Vertex Pharmaceuticals Incorporated today announced multiple program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 43rd Annual J.P. Morgan ...

Vertex Pharmaceuticals Incorporated (VRTX), headquartered ... author and do not necessarily reflect those of Nasdaq, Inc. With headquarters in the heart of Chicago's financial district, Barchart ...

Jason Kim has been appointed chief financial officer at Enveda Biosciences, a biotechnology company using artificial ...

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...